Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Thematic (Sector/Industry)

<ul>
<li>India's nuclear power capacity is projected to surge <strong>2.7 times by 2031</strong>, reaching 22.3 GW and creating a lucrative investment landscape. </li>
<li>This expansion will unlock opportunities for companies like <a href="https://www.smartkarma.com/entities/bharat-heavy-electricals" target="_blank" data-smartkarma-citation="entities:460:1" rel="noopener">Bharat Heavy Electricals (BHEL IN)</a>, <a href="https://www.smartkarma.com/entities/walchandnagar-industries" target="_blank" data-smartkarma-citation="entities:9114:1" rel="noopener">Walchandnagar Industries (WI IN)</a>, and <a href="https://www.smartkarma.com/entities/hindustan-construction-co" target="_blank" data-smartkarma-citation="entities:6446:1" rel="noopener">Hindustan Construction Co (HCC IN)</a> in manufacturing, construction, and auxiliary services. </li>
<li>The rollout of 50 Bharat Small Reactors (BSRs) presents a particularly enticing prospect with a projected investment of Rs. 2,00,000 Crore.</li>
</ul>


India's nuclear power capacity is projected to surge 2.7 times by 2031, reaching 22.3 GW and creating a lucrative investment landscape. 
This expansion will unlock opportunities for companies like Bharat Heavy Electricals (BHEL IN), Walchandnagar Industries (WI IN), and Hindustan Construction Co (HCC IN) in manufacturing, construction, and auxiliary services. 
The rollout of 50 Bharat Small Reactors (BSRs) presents a particularly enticing prospect with a projected investment of Rs. 2,00,000 Crore.


Thematic Report: India's Nuclear Power Boom: A 2.7x Growth Story

Japan Specialist

Mark Chadwick

<ul>
<li>U.S. stocks rebounded Friday after inflation data revealed a slowdown in price increases for November, with the core PCE index coming in below expectations</li>
<li>Despite the rally, all three major indices ended the week in the red, with the Nasdaq losing 1.8% and both the Dow and S&amp;P down 2%</li>
<li>Nippon Sanso will acquire Australia and New Zealand's Core Gas Group for AUD 770 million (¥75 billion)</li>
</ul>


U.S. stocks rebounded Friday after inflation data revealed a slowdown in price increases for November, with the core PCE index coming in below expectations
Despite the rally, all three major indices ended the week in the red, with the Nasdaq losing 1.8% and both the Dow and S&amp;P down 2%
Nippon Sanso will acquire Australia and New Zealand's Core Gas Group for AUD 770 million (¥75 billion)


Global Healthcare Analyst

Tina Banerjee

<ul>
<li>After two rejections, Mesoblast has finally received FDA approval for its first drug. Celltrion has received FDA approval for its Stelara biosimilar, which will be launched in February 2025.</li>
<li>Peptidream has become eligible for a milestone payment. Sumitomo Pharma is strengthening R&amp;D for regenerative medicine and cell therapy business. Astellas Pharma in-licenses technology for developing neurology drugs.</li>
<li>Hansoh Pharmaceutical granted an exclusive global license to Merck for its pre-clinical drug candidate. Lupin received FDA approval to market generic version of blockbuster Descovy tablets.</li>
</ul>


After two rejections, Mesoblast has finally received FDA approval for its first drug. Celltrion has received FDA approval for its Stelara biosimilar, which will be launched in February 2025.
Peptidream has become eligible for a milestone payment. Sumitomo Pharma is strengthening R&amp;D for regenerative medicine and cell therapy business. Astellas Pharma in-licenses technology for developing neurology drugs.
Hansoh Pharmaceutical granted an exclusive global license to Merck for its pre-clinical drug candidate. Lupin received FDA approval to market generic version of blockbuster Descovy tablets.


APAC Healthcare Weekly (Dec 22)- Mesoblast, Celltrion, Peptidream, Astellas, Hansoh, Lupin

<ul>
<li>Global oil demand growth is slowing, with projections to reach 103.8 mb/d in 2025. OPEC+ is delaying production increases amid weaker demand &amp; rising competition from non-OPEC producers like U.S.</li>
<li>Geopolitical instability, a renewable energy shift, and challenges like China's slowdown and high global interest rates are reshaping oil market dynamics, affecting prices and economic strategies.</li>
<li>OPEC's influence is waning as non-OPEC players expand and renewable energy adoption grows. The oil market's evolution highlights the urgent need for diversification in energy strategies.</li>
</ul>


Global oil demand growth is slowing, with projections to reach 103.8 mb/d in 2025. OPEC+ is delaying production increases amid weaker demand &amp; rising competition from non-OPEC producers like U.S.
Geopolitical instability, a renewable energy shift, and challenges like China's slowdown and high global interest rates are reshaping oil market dynamics, affecting prices and economic strategies.
OPEC's influence is waning as non-OPEC players expand and renewable energy adoption grows. The oil market's evolution highlights the urgent need for diversification in energy strategies.


Global Oil Market 2025: US, OPEC+ and Much More..

<ul>
<li>The Nikkei 225 ended the week down 1.9% at 38,701, with investors cautious ahead of key central bank decisions</li>
<li>The Bank of Japan kept interest rates steady at 0.25% on Thursday, deferring potential rate hikes amidst global economic uncertainty</li>
<li>Nissan's stock surged +24% this week following reports of potential merger talks with Honda and Mitsubishi Motors.</li>
</ul>


The Nikkei 225 ended the week down 1.9% at 38,701, with investors cautious ahead of key central bank decisions
The Bank of Japan kept interest rates steady at 0.25% on Thursday, deferring potential rate hikes amidst global economic uncertainty
Nissan's stock surged +24% this week following reports of potential merger talks with Honda and Mitsubishi Motors.


Japan Weekly | Nikkei Slides Amid Cautious Sentiment; Nissan, Park24, Kadokawa

Thematic (Sector/Industry)
Thematic (Sector/Industry) Insights

Thematic Report: India's Nuclear Power Boom: A 2.7x Growth Story

India's nuclear power capacity set to surge 2.7 times by 2031, creating investment opportunities for companies like BHEL, Walchandnagar & HCC .

Nimish Maheshwari

Ohayo Japan | Friday Bounce

U.S. stocks rebounded on Friday due to lower inflation data, but all major indices ended the week in the red. Nippon Sanso to acquire Core Gas...

Mark Chadwick

APAC Healthcare Weekly (Dec 22)- Mesoblast, Celltrion, Peptidream, Astellas, Hansoh, Lupin

Mesoblast got FDA approval for its first drug, while Betta Pharma, Celltrion, and Lupin also received some major FDA approvals. Pharma companies...

Tina Banerjee

Global Oil Market 2025: US, OPEC+ and Much More..

Global oil demand growth is slowing, reshaping market dynamics as OPEC's influence wanes and renewable energy adoption grows, highlighting the...

Nimish Maheshwari

Japan Weekly | Nikkei Slides Amid Cautious Sentiment; Nissan, Park24, Kadokawa

Investors cautious as Nikkei 225 drops 1.9% ahead of central bank decisions, while Nissan's stock surges 24% on merger talks with Honda and...

Mark Chadwick

Thematic Report: India's Nuclear Power Boom: A 2.7x Growth Story

​India's nuclear power capacity set to surge 2.7 times by 2031, creating investment opportunities for companies like BHEL, Walchandnagar & HCC .

Nimish Maheshwari

Ohayo Japan | Friday Bounce

​U.S. stocks rebounded on Friday due to lower inflation data, but all major indices ended the week in the red. Nippon Sanso to acquire Core Gas...

Mark Chadwick

APAC Healthcare Weekly (Dec 22)- Mesoblast, Celltrion, Peptidream, Astellas, Hansoh, Lupin

Mesoblast got FDA approval for its first drug, while Betta Pharma, Celltrion, and Lupin also received some major FDA approvals. Pharma companies...

Tina Banerjee

Global Oil Market 2025: US, OPEC+ and Much More..

​Global oil demand growth is slowing, reshaping market dynamics as OPEC's influence wanes and renewable energy adoption grows, highlighting the...

Nimish Maheshwari

Japan Weekly | Nikkei Slides Amid Cautious Sentiment; Nissan, Park24, Kadokawa

​Investors cautious as Nikkei 225 drops 1.9% ahead of central bank decisions, while Nissan's stock surges 24% on merger talks with Honda and...

Mark Chadwick

India's nuclear power capacity set to surge 2.7 times by 2031, creating investment opportunities for companies like BHEL, Walchandnagar & HCC .

U.S. stocks rebounded on Friday due to lower inflation data, but all major indices ended the week in the red. Nippon Sanso to acquire Core Gas...

Global oil demand growth is slowing, reshaping market dynamics as OPEC's influence wanes and renewable energy adoption grows, highlighting the...

Investors cautious as Nikkei 225 drops 1.9% ahead of central bank decisions, while Nissan's stock surges 24% on merger talks with Honda and...